The Value of Early-Phase Medical Communication Planning

Life Sciences, Pharmaceutical Regulation, Pharmaceutical, Drug Discovery & Development,
  • Tuesday, April 13, 2021 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
  • 60 min

Ensuring That Key Stakeholders are Engaged and Aligned

Medical communication planning is an integral component in the journey of a new drug or therapy, from pipeline development to regulatory approval and market access.

The most visible results of a medical communication plan are external communications such as congress presentations and peer-reviewed publications. However, medical communication planning also encompasses a number of internal initiatives that inform how a company presents itself and its therapies to external audiences. Ideally, many of these activities should occur early in product development: after late preclinical data have confirmed the suitability of the candidate drug for clinical development, but before phase 2 clinical data become available. These activities often include:

  • Developing a strategic publication plan, scientific communication platform, and lexicon
  • Gathering information on the target disease and competitor landscape
  • Identifying and forming partnerships with key external experts in preparation for publication of clinical data in accordance with industry guidelines

These internal activities inform and ultimately drive external communications—not only the ‘when,’ ‘where’ and ‘how’ key data are released, but also development of the narrative that establishes the positioning of the product and disease area with external partners, payers, regulators and healthcare providers.

Early initiation of medical communication planning ensures that key stakeholders are well-educated in the therapeutic area, unmet needs, product and key competitors are aligned on preferred language and strategic objectives.

Register for this webinar to learn about:

  • Internal activities and external communications that can be performed early to prepare for late clinical stage development and eventual product launch
  • The benefits and risks of early-phase medical communication planning



Gerry Johnson, Senior Scientific Manager, Global Medical Communications, ICON

Gerry has worked in medical communications for more than 16 years and is skilled in the development of strategic, impactful, accurate, and timely medical and scientific content. He has directed strategic and tactical initiatives across a variety of assets and therapeutic areas (including infectious diseases, neurology, oncology and haematology) in pre- through post-launch phases.

Message Presenter

Amanda Kelly, Senior Manager, Publications and Scientific Communications, Incyte

Over the past 10 years, Amanda has held medical communications positions in a non-profit organization, a medical communications agency, and a mid-size biopharmaceutical company, gaining experience in both executing and developing strategic publication plans in collaboration with cross-functional colleagues. These roles have provided her with a broad range of experience in cardiology, neurology, oncology and haematology.

Message Presenter

Kelly Mayer, Senior Account Manager, Global Medical Communications, ICON

Kelly, an active ISMPP member, has over 17 years of experience in sales, research and medical communications. As part of ICON’s Global Medical Communications practice, she supports the development and strategic planning for a broad range of medical education and publication deliverables, including abstracts, posters, manuscripts, congress presentations/support, training materials and competitor/literature analyses.

Message Presenter

Cory Pfeiffenberger, Scientific Manager, Global Medical Communications, ICON

Cory has over 7 years’ experience in medical communications, with experience in traditional clinical research publications, strategic projects, training materials, medical information response letters, investigator brochures and AMCP formulary dossiers. As part of ICON’s Global Medical Communications practice, Cory spends the majority of his time supporting assets in therapeutic areas such as oncology, haematology and immunology.

Message Presenter

Who Should Attend?

This programme will be beneficial for pharmaceutical, medical device, and biotechnology professionals working in the following areas:

  • Medical
  • Medical affairs
  • Field medical
  • Medical training
  • Publications
  • Scientific communications
  • Clinical development
  • Commercial
  • Legal & regulatory
  • Early assets
  • Patient-centricity

What You Will Learn

Please join panelists from ICON as they discuss:

  • Internal activities and external communications that can be performed early to prepare for late clinical stage development and eventual product launch
  • The benefits and risks of early-phase medical communication planning

Xtalks Partner

ICON plc

ICON plc is a global provider of outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 98 locations in 40 countries and has approximately 15,200 employees.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account